iTeos Pharma (ITOS) - מקדם חוב לטווח ארוך להון

iTeos Therapeutics (ITOS) is implementing robotic systems to accelerate antibody selection in oncology, relieving scientists of repetitive tasks. This daily price chart on the GURU.Markets platform currently reflects a level of 0.01. The business's success relies on partnerships with industry behemoths and the availability of funds for final testing. The company operates in the growing tumor-fighting segment, where medical demand remains consistently high.

The stability of iTeos Therapeutics (ITOS) relies on the trust of the oncology community and the support of a global pharmaceutical partner. This long-term financial debt sustainability metric measures the proportion of liabilities exceeding one year relative to equity. An increase in the ratio signals a growing debt load on the asset structure. A downward trend in the curve confirms the autonomy of research and development funding. This allows for an objective assessment of the company's investment attractiveness and fair value.